title: Characteristics of Severe Retinopathy of Prematurity in Infants with Birth Weight above 1500 Grams at a Referral Center in Turkey.
abstract: OBJECTIVE
  To demonstrate the clinical characteristics and treatment outcomes of severe retinopathy of prematurity (ROP) in preterm infants with birth weight (BW) above 1500 g in Turkey.
  
  
  METHODS
  A retrospective review of 5920 ROP records was performed in Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital. The records were obtained from ROP treatment center of the same institute between 2011 and 2016. The data comprised the demographic and clinical characteristics including, gestational age, BW, systemic risk factors, zone and stage of ROP, ROP type, treatment modality, treatment outcomes and inborn/outborn status of the babies.
  
  
  RESULTS
  A total of 36 infants (71 eyes) with severe ROP and BW> 1500 g were retrieved. There were 30 infants (83.3%) with type 1 ROP and 6 infants (16.7%) with aggressive posterior ROP (APROP). 3 infants (8.3%) were born at our hospital whereas 33 (91.7%) were referred from outer private neonatal intensive care unit (NICU) centers. Zone I APROP was detected during the initial screening. 21 infants (58.3%) underwent laser treatment while 15 (41.7%) received intravitreal bevacizumab (IVB) injections. No unfavorable structural outcome was observed following either treatment modality.
  
  
  CONCLUSIONS
  Severe ROP may occur in heavier preterm infants. Laser treatment and IVB injections were useful in selected cases. Presence of APROP at first examination suggests an earlier screening in heavier babies. Standardization of private NICU centers as well as establishing a national ROP protocol is necessary in Turkey.
authors.affiliation: Department of Ophthalmology, Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Gunay
authors.affiliation: Department of Ophthalmology, Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
authors.forename: Gokhan
authors.initials: G
authors.lastname: Celik
authors.affiliation: Department of Neonatology, Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
authors.forename: Abdulhamit
authors.initials: A
authors.lastname: Tuten
authors.affiliation: Department of Neonatology, Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
authors.forename: Guner
authors.initials: G
authors.lastname: Karatekin
authors.affiliation: Department of Ophthalmology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
authors.forename: Handan
authors.initials: H
authors.lastname: Bardak
authors.affiliation: Department of Pediatrics, Division of Neonatology, Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey.
authors.forename: Fahri
authors.initials: F
authors.lastname: Ovali
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal / Q000458:organization & administration; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods*; D008297:Male; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014421:Turkey
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab